Dubermatinib(TP-0903)

In pancreatic cancer cells (PSN-1), Dubermatinib (TP-0903) shows strong antiproliferative activity with IC50 of 6 M. It also induces strong G2/M arrest by potently inhibiting Aurora A and B. [1] In CLL B cells from all the patients with CLL, this compound causes a dose-dependent induction of massive apoptosis by targeting phosphorylated Axl, and overcomes CLL BMSC-mediated protection of CLL B cells from apoptosis. ^[2]

Dubermatinib (TP-0903), when administered intracerebroventricularly at 2.5 nM in the adult rat hippocampus, significantly increases the number of newly generated cells and extends survival of hippocampal cells. ^[3] In mice, this compound (20 μg/g, i.p.) effectively prevents GC-induced neonatal cerebellar developmental abnormalities. ^[4]

• Axl Kinase activity assay

  Test compounds, including Dubermatinib (TP-0903), are diluted to desired concentrations in kinase reaction buffer (50 mM HEPES pH 7.5, 10 mM MgCl², 1 mM EGTA, 2 mM DTT, and 0.01% v/v Tween-20) and are briefly incubated with Axl kinase. The Axl kinase used is recombinant human Axl kinase (catalytic domain, amino acids 473-894) with a histidine tag. The reaction is initiated by the addition of ATP and labeled poly-GT substrate (poly Glu:Tyr, 4:1 polymer). Concentration of the various components in the assay (10 µL reaction volume) are: 1% DMSO, 93 ng/mL Axl kinase, 20 µM ATP, and 200 nM poly-GT substrate. Following addition of ATP and poly-GT substrate, incubation is for 60 min at room temperature, the enzyme reaction is stopped by addition of 10 µL terbium-labeled anti-phosphotyrosine PY20 antibody in EDTA-containing buffer. Final concentration of EDTA and antibody after addition to the reaction is 10 mM and 2 nM, respectively. The terbium conjugated antibody generates a time-resolved FRET signal with the molecule (bound to the poly-GT substrate) when the substrate is phosphorylated. After one hour incubation at room temperature, fluorescence is measured with excitation of 320 nm and dual emission of 495 and 520 nm on an EnVision microplate reader. Signal is expressed in terms of a TR-FRET ratio (fluorescence intensity at 520 nm to 495 nm).

• Cell lines

  PSN-1 cells

• Concentrations

  --

• Incubation Time

  96 hours

• Method

  For cell proliferation assays with Dubermatinib (TP-0903), 45 µL containing 1000 cells per well are seeded into solid white 384-well plates in appropriate cell growth media containing 10% FBS and incubated overnight at 37 °C and 5% CO₂. The following day, this compound is diluted in serum free growth media to 10x desired concentrations and 5 µL is added to each well. Combined compound and cells are incubated for 96 hours. Following incubation, 40 µL of ATP-Lite solution is added to each well, incubated for an additional 10 minutes at room temperature and luminescence is measured on an EnVision microplate reader. Percent cell viability for it is calculated by comparing treated wells to appropriate controls (e.g. vehicle treated) included on each plate.